H yperglycemia is known to be the proximate cause of microvascular complications of the eye, kidneys, and nerves in patients with diabetes. This was indicated by animal studies and clinical and epidemiological research (1-3) and has been firmly established by clinical trials (4, 5) . The Diabetes Control and Complications Trial convincingly demonstrated that intensive treatment of patients with type 1 diabetes can substantially delay the onset and slow the progression of retinopathy, nephropathy, and neuropathy (4) . The Ohkubo study showed that patients with type 2 diabetes can benefit from intensive treatment of glycemia about as much as patients with type 1 diabetes (5) .
Despite the ravages wrought by microvascular disease, mortality is often considered by the public health community to be the key marker of the impact of a disease. Mortality rates for patients with diabetes are about twice those of people without diabetes. Cardiovascular diseases account for 50-60% of deaths in diabetes; coronary heart disease alone is the cause of 40-50% of deaths and confers a two-to fourfold increased mortality risk compared with nondiabetic adults (6) .
Glycemia is clearly related to microvascular complications. Diabetic microvascular disease is uncommon in people who do not meet diagnostic criteria for diabetes (7, 8) and the reduction in microvascular complications in diabetic patients is proportional to the reduction in hyperglycemia (4). Does a proportional or threshhold relationship exist between glycemia and mortality, particularly mortality from heart disease? This has been the subject of many investigations, dating back at least to a series of papers that form an international collaborative effort to investigate this issue (9) . This was also the subject of two recent commentaries (10, 11) . Unlike the clear relationship of glycemia with microvascular disease, a relationship with macrovascular disease and mortality is clouded by the many other risk factors that cause cardiovascular disease and increase mortality risk in general.
In this issue of Diabetes Care, Balkau et al. (12) provide further information on the relationship of glycemia to mortality in initially nondiabetic adults. They investigated mortality in middle-aged men who did not have diabetes at the beginning of a 20-year observation period. The men were drawn from the Helsinki Policeman Study, the Whitehall (U.K.) Study, and the Paris Prospective Study They were categorized according to the percentile distribution of fasting (n = 6,629) and 2-h postchallenge (n = 17,785) glucose in 1967-1972, and mortality was ascertained during the subsequent 20 years. Whether diabetes developed during this follow-up period was not determined.
Death rates increased with increasing percentile of fasting glucose. However, statistically significant elevated mortality, adjusted for multiple risk factors for mortality, was found only for those in the >97.5th percentile of fasting glucose compared with those in the <80th percentile. The hazard ratio for this comparison was 1.6 for all causes, cardiovascular disease, and neoplasms and was 1.9 for coronary heart disease. Hazard ratios for those in the 80th to 90th, 90th to 95th, and 95th to 97.5th percentiles of fasting glucose compared with those in the <80th percentile were not statistically significant. Similar results were found for 2-h postchallenge glucose and heart disease mortality, with a statistically significant elevated risk only in the >97.5th percentile; the multiply-adjusted hazard ratio was 1.3. For mortality from all causes combined and from neoplasms, statistically significant results were found for men in the 80th to 90th, 90th to 95th, 95th to 97.5th, and >97.5th percentiles compared with those in the <80th percentile; the hazard ratios ranged from 1.1 to 1.2 for those in the 80th to 90th percentile to 1.3 to 1.4 for those in the >97.5th percentile.
In sum, this very large and long-term study indicates that glycemia can be implicated as a risk factor only for all-cause mortality in men in the highest 2.5th percentile of fasting glucose, for heart disease mortality in men in the highest 2.5th percentile of 2-h glucose, and for all-cause and cancer mortality in men in the >20th percentile of 2-h glucose.
The degree of risk associated with 2-h glucose was a 10-40% elevation in mortality compared with men in the <80th percentile. This degree of elevation of mortality risk is not great and certainly does not approach the 100-300% elevated risk (relative risk of 2-4) found for adults with diabetes versus adults without diabetes in other studies. Can the slight elevation in risk associated with 2-h glucose in the present report (and the larger relative risk for the highest 2.5th percentile of fasting glucose) be attributed to a portion of the upper-centile cohort becoming diabetic during the 20-year period and adding their markedly increased risk of death to a relatively low risk of the remaining nondiabetic subjects of the cohort? This possibility is acknowledged by Balkau et al. (12) . It is made more likely by the fact that a statistically significant relationship of coronary heart disease with glycemia was found only in this 20-year mortality follow-up and not in the 11-or 15-year follow-up studies (13) . The slight elevation in mortality risk was not confined to cardiovascular disease but also occurred for neoplasms. Thus, a high but nondiabetic blood glucose level may be a nonspecific marker for increased risk of death for people without diabetes. Other studies have shown that it is a specific marker for increased risk of development of diabetes.
Although blood glucose has not been clearly demonstrated to be a strong risk factor for mortality in nondiabetic men, diabetes is a strong and established risk factor for cardiovascular morbidity and mortality. Multiple mechanisms exist for the increased incidence of cardiovascular disease in diabetes and for the increased morbidity and mortality from cardiovascular disease after it occurs (14, 15) . High triglyceride levels, low HDL cholesterol, and a shift in the lipoprotein density profile to smaller, denser, more atherogenic particles increase the risk of plaque formation. Higher rates of hypertension are present among diabetic patients and nocturnal hypertension is more common, presumably due to autonomic dysfunction (16) . In addition to increased risk of plaque formation, diabetes is associated DIABETES CARE, VOLUME 21, NUMBER 3, MARCH 1998
Editorial with a greater tendency toward thrombogenesis, by virtue of higher levels of fibrinogen and reduced nbrinolytic activity The thrombogenic profile correlates with glycemia and with insulin levels, although it is not proven that hyperglycemia or hyperinsulinemia are etiological either alone or in combination (17, 18) . Finally, the death rate for people who have coronary heart disease (the case fatality rate) is higher among those who also have diabetes. Increased mortality due to congestive heart failure in the first year after myocardial infarction is a major risk for diabetic patients. This risk remains even after considering the severity of the coronary artery disease and may relate to altered myocardial energetics and remodeling of the heart after the infarct (19) . Thus, multiple mechanisms may underlie the greater frequency of cardiovascular disease among patients with diabetes as well as their higher morbidity and mortality.
From a practical point of view, what can physicians do to reduce this excess morbidity and mortality? More intensive treatment of dyslipidemia and hypertension has been recommended for patients with diabetes, even in the absence of known cardiovascular disease. Thus, lowering LDL cholesterol to < 100 mg/dl and blood pressure to < 135/85 mmHg has been recommended for patients with diabetes (20) . Smoking cessation is particularly important in diabetes, since smoking increases both microvascular and macrovascular disease risk. Use of aspirin to decrease thrombogenesis also seems reasonable, as does the use of beta-blockers and ACE inhibitors after myocardial infarction (21, 22) . Indeed, beta-blockers and ACE inhibitors appear to confer much greater benefit to diabetic patients than to those without diabetes. Patients with diabetes, at least a subset of those with more extensive disease, appear to fare better with coronary artery bypass grafting (CABG) than with percutaneous transluminal coronary angioplasty (PTCA) (23). Thus, there are many interventions that are likely to reduce cardiovascular disease morbidity and mortality in diabetes (24) .
Important questions remain. Is control of glycemia, per se, important in reducing cardiovascular risk, and if so, what level of control will be required? Intensive treatment of diabetes with insulin in the immediate postinfarction period appears to increase survival after 1 year; further study is needed of the effects of glycemic control on the prognosis of cardiovascular disease (25).
Glycemia may not be an independent risk factor for mortality in people who do not have diabetes, except at the highest nondiabetic glucose values. However, many of these individuals do have increased levels of established risk factors for mortality, particularly mortality from cardiovascular disease. Many also have increased levels of risk factors for development of diabetes, at which point their risk for mortality becomes clearly greater. Thus, it behooves the medical community to focus on control of both of these sets of risk factors. 
